Intermountain Medical Center Heart Institute, Salt Lake City, Utah, USA; Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California, USA.
Intermountain Medical Center Heart Institute, Salt Lake City, Utah, USA; Cardiology Division, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Am Heart J. 2022 Feb;244:125-134. doi: 10.1016/j.ahj.2021.11.001. Epub 2021 Nov 17.
Medication adherence is generally low and challenging to address because patient actions control healthcare delivery outside of medical environments. Behavioral nudging changes clinician behavior, but nudging patient decision-making requires further testing. This trial evaluated whether behavioral nudges can increase statin adherence, measured as the proportion of days covered (PDC).
In a 12-month parallel-group, unblinded, randomized controlled trial, adult patients in Intermountain Healthcare cardiology clinics were enrolled. Inclusion required an indication for statins and membership in SelectHealth insurance. Subjects were randomized 1:1 to control or nudges. Nudge content, timing, frequency, and delivery route were personalized by CareCentra using machine learning of subject motivations and abilities from psychographic assessment, demographics, social determinants, and the Intermountain Mortality Risk Score. PDC calculation used SelectHealth claims data.
Among 182 subjects, age averaged 63.2±8.5 years, 25.8% were female, baseline LDL-C was 82.5±32.7 mg/dL, and 93.4% had coronary disease. Characteristics were balanced between nudge (n = 89) and control arms (n = 93). The statin PDC was greater at 12 months in the nudge group (PDC: 0.742±0.318) compared to controls (PDC: 0.639±0.358, P = 0.042). Adherent subjects (PDC ≥80%) were more concentrated in the nudge group (66.3% vs controls: 50.5%, P = 0.036) while a composite of death, myocardial infarction, stroke, and revascularization was non-significant (nudges: 6.7% vs control: 10.8%, P = 0.44).
Persuasive behavioral nudges driven by artificial intelligence resulted in a clinically important increase in statin adherence in general cardiology patients. This precision patient decision support utilized computerized nudge design and delivery with minimal on-going human input.
药物依从性通常较低,且难以解决,因为患者的行为控制着医疗环境之外的医疗保健服务的提供。行为推动改变了临床医生的行为,但推动患者决策需要进一步的测试。本试验评估了行为推动是否可以提高他汀类药物的依从性,以比例日覆盖(PDC)来衡量。
在一项为期 12 个月的平行组、非盲、随机对照试验中,招募了 Intermountain Healthcare 心脏病学诊所的成年患者。纳入标准需要他汀类药物的适应症和 SelectHealth 保险。受试者以 1:1 的比例随机分为对照组或推动组。推动内容、时间、频率和传递途径由 CareCentra 根据对受试者动机和能力的心理评估、人口统计学、社会决定因素和 Intermountain 死亡率风险评分的机器学习进行个性化设置。PDC 计算使用 SelectHealth 理赔数据。
在 182 名受试者中,年龄平均为 63.2±8.5 岁,25.8%为女性,基线 LDL-C 为 82.5±32.7mg/dL,93.4%患有冠心病。推动组(n=89)和对照组(n=93)的特征平衡。在 12 个月时,推动组的他汀类药物 PDC 更高(PDC:0.742±0.318),而对照组(PDC:0.639±0.358,P=0.042)。依从性高的受试者(PDC≥80%)更集中在推动组(66.3% vs 对照组:50.5%,P=0.036),而死亡、心肌梗死、中风和血运重建的综合发生率无显著差异(推动组:6.7% vs 对照组:10.8%,P=0.44)。
由人工智能驱动的有说服力的行为推动在一般心脏病患者中导致了他汀类药物依从性的临床显著增加。这种精确的患者决策支持利用了计算机化的推动设计和传递,几乎不需要持续的人工输入。